ES2158956T3 - Formulacion de cafeina de cesion sostenida. - Google Patents

Formulacion de cafeina de cesion sostenida.

Info

Publication number
ES2158956T3
ES2158956T3 ES95936707T ES95936707T ES2158956T3 ES 2158956 T3 ES2158956 T3 ES 2158956T3 ES 95936707 T ES95936707 T ES 95936707T ES 95936707 T ES95936707 T ES 95936707T ES 2158956 T3 ES2158956 T3 ES 2158956T3
Authority
ES
Spain
Prior art keywords
composition
caffin
sustained
assignment
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95936707T
Other languages
English (en)
Inventor
Francoise Chauffard
Marc Y A Enslen
Pierre Tachon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Application granted granted Critical
Publication of ES2158956T3 publication Critical patent/ES2158956T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMPOSICION PARA LA LIBERACION CONTROLADA DE UN ESTIMULANTE DE XANTINA O DERIVADO DE XANTINA, QUE INCLUYE MICROPARTICULAS CON UNA MATRIZ BIODEGRADABLE DE LA MENOS UN MATERIAL SOLUBLE EN AGUA Y EL ESTIMULANTE, ESTANDO DICHO ESTIMULANTE EN FORMA DE PARTICULAS SOLIDAS QUE SE DISTRIBUYEN DE FORMA UNIFORME BASICAMENTE A TRAVES DE LA MATRIZ. TAMBIEN SE REFIERE UN METODO PARA ELABORAR ESTA COMPOSICION MEDIANTE LA DISPERSION DEL ESTIMULANTE EN LA FORMA DE UNA VARIEDAD DE PARTICULAS SOLIDAS EN UNA MATRIZ BIODEGRADABLE. ESTA COMPOSICION PUEDE ADMINISTRARSE ORALMENTE DE FORMA VENTAJOSA PARA AUMENTAR LA ALERTA DE UN INDIVIDUO.
ES95936707T 1994-12-16 1995-11-27 Formulacion de cafeina de cesion sostenida. Expired - Lifetime ES2158956T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/357,689 US5744164A (en) 1994-12-16 1994-12-16 Sustained release microparticulate caffeine formulation

Publications (1)

Publication Number Publication Date
ES2158956T3 true ES2158956T3 (es) 2001-09-16

Family

ID=23406640

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95936707T Expired - Lifetime ES2158956T3 (es) 1994-12-16 1995-11-27 Formulacion de cafeina de cesion sostenida.

Country Status (21)

Country Link
US (2) US5744164A (es)
EP (2) EP0716853A1 (es)
JP (1) JPH10510529A (es)
AR (1) AR002947A1 (es)
AT (1) ATE201986T1 (es)
AU (1) AU694810B2 (es)
CA (1) CA2208149C (es)
CO (1) CO4600671A1 (es)
DE (1) DE69521328T2 (es)
DK (1) DK0789562T3 (es)
ES (1) ES2158956T3 (es)
GR (1) GR3036501T3 (es)
HK (1) HK1000878A1 (es)
IL (1) IL116066A (es)
NZ (1) NZ295245A (es)
PE (1) PE55396A1 (es)
PT (1) PT789562E (es)
RU (1) RU2144353C1 (es)
TR (1) TR199501560A2 (es)
WO (1) WO1996018389A1 (es)
ZA (1) ZA9510687B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6122496A (en) * 1995-06-20 1997-01-22 Pharma-Vinci A/S A method of preparing an oral preparation provided on the outer side with an enteric coating, as well as an oral preparation obtained by the method
US6949264B1 (en) 1996-11-27 2005-09-27 Wm. Wrigley Jr. Company Nutraceuticals or nutritional supplements and method of making
US6586023B1 (en) 1998-12-15 2003-07-01 Wm. Wrigley Jr. Company Process for controlling release of active agents from a chewing gum coating and product thereof
US6531114B1 (en) 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
US7163705B2 (en) * 1998-12-15 2007-01-16 Wm. Wrigley Jr. Company Coated chewing gum product and method of making
US6627234B1 (en) 1998-12-15 2003-09-30 Wm. Wrigley Jr. Company Method of producing active agent coated chewing gum products
US6773716B2 (en) 1999-04-06 2004-08-10 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US20020159956A1 (en) * 1999-04-06 2002-10-31 Ream Ronald L. Over-coated chewing gum formulations
US7935362B2 (en) * 1999-04-06 2011-05-03 Wm. Wrigley Jr. Company Over-coated product including consumable center and medicament
US6426090B1 (en) * 1999-04-06 2002-07-30 Wm. Wrigley Jr. Company Over-coated product including tableted center and medicament
US6355265B1 (en) 1999-04-06 2002-03-12 Wm. Wrigley Jr. Company Over-coated chewing gum formulations
US6322806B1 (en) 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center
US6663849B1 (en) 2000-09-01 2003-12-16 Wm. Wrigley Jr. Company Antacid chewing gum products coated with high viscosity materials
US6569472B1 (en) 2000-09-01 2003-05-27 Wm. Wrigley Jr. Company Coated chewing gum products containing antacid and method of making
US6645535B2 (en) 1999-09-02 2003-11-11 Wm. Wrigley Jr. Company Method of making coated chewing gum products containing various antacids
US6541048B2 (en) 1999-09-02 2003-04-01 Wm. Wrigley Jr. Company Coated chewing gum products containing an acid blocker and process of preparing
US9387168B2 (en) 1999-09-20 2016-07-12 Jack Barreca Chewing gum with tomatidine
US6491540B1 (en) * 1999-09-20 2002-12-10 Jack Barreca Center-filled supplement gum
US9253991B2 (en) 1999-09-20 2016-02-09 Jack Barreca Chewing gum with B vitamins
US8178150B2 (en) 2000-02-22 2012-05-15 Suzanne Jaffe Stillman Water containing soluble fiber
US7115297B2 (en) 2000-02-22 2006-10-03 Suzanne Jaffe Stillman Nutritionally fortified liquid composition with added value delivery systems/elements/additives
US7892586B2 (en) 2001-02-22 2011-02-22 Suzanne Jaffe Stillman Water containing soluble fiber
US6572900B1 (en) 2000-06-09 2003-06-03 Wm. Wrigley, Jr. Company Method for making coated chewing gum products including a high-intensity sweetener
US7115288B2 (en) * 2000-06-09 2006-10-03 Wm. Wrigley Jr. Company Method for making coated chewing gum products with a coating including an aldehyde flavor and a dipeptide sweetener
RU2166945C1 (ru) * 2000-08-08 2001-05-20 Ефимова Лариса Степановна Радиосенсибилизирующее вещество для лечения онкологических заболеваний
US6444241B1 (en) 2000-08-30 2002-09-03 Wm. Wrigley Jr. Company Caffeine coated chewing gum product and process of making
US6579545B2 (en) 2000-12-22 2003-06-17 Wm. Wrigley Jr. Company Coated chewing gum products containing an antigas agent
US7897141B2 (en) * 2002-04-01 2011-03-01 Drexel University Echogenic polymer microcapsules and nanocapsules and methods for production and use thereof
US20030220351A1 (en) * 2002-05-24 2003-11-27 Gilbert Gonzales Enteric coated caffeine tablet
EP1565062A1 (en) * 2002-11-25 2005-08-24 Phares Pharmaceutical Research N.V. Confectionery composition
US20050181044A1 (en) * 2004-02-18 2005-08-18 Jaime Romero Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract
US20050220875A1 (en) * 2004-03-31 2005-10-06 Agency For Science, Technology And Research Sustained-release tablet formulation
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
US8486452B2 (en) 2007-07-20 2013-07-16 Mylan Pharmaceuticals Inc. Stabilized tolterodine tartrate formulations
US8110226B2 (en) * 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
MX2011007819A (es) * 2009-01-22 2011-12-16 Abbott Healthcare Private Ltd Composicion farmaceutica cronoterapeutica.
US8545892B2 (en) 2009-06-26 2013-10-01 Nano Pharmaceutical Laboratories, Llc Sustained release beads and suspensions including the same for sustained delivery of active ingredients
US8992898B2 (en) 2010-04-17 2015-03-31 Shannon Elizabeth Klingman Antiperspirants and deodorants
WO2014197601A1 (en) * 2013-06-04 2014-12-11 KVK-Tech, Inc. Controlled release caffeine dosage forms
AU2015377223A1 (en) * 2015-01-12 2017-08-31 Nano Pharmaceutical Laboratories Llc Layered sustained-release microbeads and methods of making the same
KR101644154B1 (ko) * 2015-09-08 2016-07-29 주식회사 스킨앤테크 수용성 카페인 및 그 제조방법
US10582716B1 (en) 2019-06-14 2020-03-10 Lennham Pharmaceuticals, Inc. Deuterated caffeine and uses thereof
US12194046B2 (en) * 2021-03-09 2025-01-14 Lennham Pharmaceuticals, Inc. D9-caffeine compositions and uses thereof
US20250082580A1 (en) * 2021-07-30 2025-03-13 Panion & Bf Biotech Inc. Controlled-release oral formulation and preparation method thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1249219B (de) * 1958-12-22 1967-09-07 The National Cash Register Company, Dayton, Ohio (V. St. A.) Herstellen von Mikrokapseln, die eine Emulsion aus Öl in hydrophiler Flüssigkeit enthalten
US3265629A (en) * 1958-12-22 1966-08-09 Ncr Co Coating by phase separation
DE2010416B2 (de) * 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4001480A (en) * 1974-08-16 1977-01-04 Swift & Company Encapsulation process utilizing microorganisms and products produced thereby
IE55745B1 (en) * 1983-04-06 1991-01-02 Elan Corp Plc Sustained absorption pharmaceutical composition
NZ207813A (en) * 1983-06-24 1986-12-05 Dridrinks Nv Effervescent mixture:component(s)coated with water-soluble polysaccharide composition
ATE37272T1 (de) * 1983-06-24 1988-10-15 Dridrinks Nv Verfahren zum behandeln von saeuren als komponenten fuer pulverfoermige, wasserloesliche zusammensetzungen fuer getraenke mit andauernder gasabgabe.
NZ210785A (en) * 1984-01-13 1987-11-27 Battelle Development Corp Liquid dispersions of layered controlled release dosage forms
DE3403329A1 (de) * 1984-02-01 1985-08-01 Horst Dr. 4019 Monheim Zerbe Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
WO1985003436A1 (en) * 1984-02-10 1985-08-15 A/S Alfred Benzon Diffusion coated multiple-units dosage form
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
DE3537770A1 (de) * 1985-10-24 1987-04-30 Basf Ag Salze mehrwertiger kationen von polymerisaten von konjugierten dienen
US4853249A (en) * 1985-11-15 1989-08-01 Taisho Pharmaceutical Co., Ltd. Method of preparing sustained-release pharmaceutical/preparation
US5026709A (en) * 1986-04-07 1991-06-25 Rorer Pharmaceutical Corporation Method for the preparation of a theophylline sustained release pharmaceutical composition and the composition prepared thereby
WO1987006098A1 (en) * 1986-04-07 1987-10-22 Rorer International (Overseas) Inc. Method for the preparation of a sustained release pharmaceutical composition and the composition prepared thereby
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5200193A (en) * 1987-04-22 1993-04-06 Mcneilab, Inc. Pharmaceutical sustained release matrix and process
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
US4971785A (en) * 1988-03-14 1990-11-20 Spectrum Consumer Products Co., Inc. Non-alcoholic delivery system for orally ingestible active ingredients
CA2007181C (en) * 1989-01-06 1998-11-24 Angelo Mario Morella Sustained release pharmaceutical composition
US5330766A (en) * 1989-01-06 1994-07-19 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤

Also Published As

Publication number Publication date
PE55396A1 (es) 1996-12-24
JPH10510529A (ja) 1998-10-13
AU3854295A (en) 1996-07-03
DK0789562T3 (da) 2001-09-03
CA2208149A1 (en) 1996-06-20
CO4600671A1 (es) 1998-05-08
AR002947A1 (es) 1998-05-27
RU2144353C1 (ru) 2000-01-20
ZA9510687B (en) 1996-07-03
PT789562E (pt) 2001-10-30
WO1996018389A1 (en) 1996-06-20
ATE201986T1 (de) 2001-06-15
DE69521328T2 (de) 2002-01-17
IL116066A0 (en) 1996-01-31
AU694810B2 (en) 1998-07-30
EP0716853A1 (en) 1996-06-19
CA2208149C (en) 2007-03-27
NZ295245A (en) 1999-01-28
HK1000878A1 (en) 2001-10-26
US5700484A (en) 1997-12-23
EP0789562B1 (en) 2001-06-13
EP0789562A1 (en) 1997-08-20
GR3036501T3 (en) 2001-11-30
IL116066A (en) 2000-10-31
US5744164A (en) 1998-04-28
DE69521328D1 (de) 2001-07-19
TR199501560A2 (tr) 1996-07-21

Similar Documents

Publication Publication Date Title
AR002947A1 (es) Composicion para la liberacion controlada de un estimulante de xantina o de un derivado de xantina y metodo para preparar dicha composicion
DE69834195D1 (de) Stabilisierte tramadol formulierungen mit verzögerter freisetzung
ES8708182A1 (es) Un metodo para preparar una composicion que contiene tetraciclina
WO1995011008A3 (en) Methods and compositions for microencapsulation of adjuvants
CO4130178A1 (es) Composicion para el cuidado personal en forma de gel, que tiene propiedades viscoelasticas
ES2173930T3 (es) Articulos expandidos de material plastico biodegradable y un proceso para la preparacion de los mismos.
CO5070636A1 (es) Proceso para la preparacion de formas galenicas solidas con liberacion controlada de los ingredientes activos para uso peroral
BR0107874A (pt) Implante farmacêutico para controlavelmente liberar uma droga, método para controlavelmente liberar uma droga em um indivìduo, e, método para preparar o implante
AR017079A1 (es) Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.
CO5700698A2 (es) Composiciones y metodos para el cuidado oral y personal
ATE277601T1 (de) Verbesserungen bezüglich der verkapselung bioaktiver wirkstoffe
AR018704A1 (es) Parche con efecto de campo magnetico
BRPI0416590A (pt) excipientes em veìculos de distribuição de fármacos
ES2072967T3 (es) Particulas de perfume revestidas.
DK0620731T3 (da) Farmaceutisk præparat i form af en bruse- og/eller henfaldstablet eller et instantgranulat samt fremgangsmåde til fremstilling deraf
ES2130217T3 (es) Uso de tiloxapol como dispersante y estabilizante de nanoparticulas.
ES2145118T3 (es) Derivados de acidos grasos y composiciones farmaceuticas que los contienen.
BRPI0707044B8 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
GR3004710T3 (es)
ATE258044T1 (de) Verfahren zur herstellung einer mit bändern versehenen dosisform zur verlängerten freisetzung eines wirkstoffs
MXPA02007059A (es) Composicion de autobronceado que contiene un ester n-acilado de aminoacido y un agente de autobronceado.
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
BR0113376A (pt) Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculina
AR008799A1 (es) Composicion de vacuna para prevenir o tratar el paludismo; uso de dicha composicion para elaborar medicamentos y metodo para dicha profilaxis y dichotratamiento
ES2131318T3 (es) Pelets.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 789562

Country of ref document: ES